1% Glycopyrronium bromide improves long-term outcomes of primary axillary hyperhidrosis

Recent study published in the Journal of the European Academy of Dermatology and Venereology suggests that 1% glycopyrronium bromide (GPB) cream is an effective and safe long-term treatment option for patients with severe Primary axillary hyperhidrosis (PAHH).

Primary axillary hyperhidrosis is a condition that causes excessive sweating in the armpits, leading to significant discomfort and reduced quality of life for patients. The team led by Rolf-Markus Szeimies aimed to evaluate the long-term efficacy and safety of a 1% GPB cream in patients with severe PAHH.

The study was a Phase 3b, open-label trial that included 518 patients with severe PAHH who were treated with 1% GPB cream once daily for 4 weeks, followed by a flexible dosing scheme for up to 72 weeks. The primary endpoint was the absolute change in sweat production from baseline to week 12, and secondary endpoints included the severity of PAHH and its impact on quality of life.

The findings of the study were:

Treatment with 1% GPB cream significantly reduced sweat production by 65.6% from baseline to week 12, and this effect was maintained throughout the 72-week study period.

Patients' quality of life was also significantly improved at all study time points compared to baseline, as assessed by Hyperhidrosis Quality of Life Index and Dermatology Life Quality Index.

The treatment was safe and well-tolerated, with only mild to moderate adverse drug reactions reported, such as dry mouth and application site erythema.

Overall, this s Authors suggest that the significant reduction in sweat production and improvement in quality of life observed in this study could lead to better management of this condition and improved outcomes for patients.

Source:

Szeimies, R., Abels, C., Kilic, A., Reich, H., Berger, B., Schulze zur Wiesche, E., Schramm, K., Litzka, L., Heimstaedt‐Muskett, S., & Masur, C. (2023). Long‐term efficacy and safety of 1% glycopyrronium bromide cream in patients with severe primary axillary hyperhidrosis: Results from a Phase 3b trial. In Journal of the European Academy of Dermatology and Venereology. Wiley. https://doi.org/10.1111/jdv.18843